RecruitingNot ApplicableNCT07226596

Non-Abstinence Outcomes in Methamphetamine Use Disorder

Advancing Non-Abstinence Outcomes in the Treatment of Methamphetamine Use Disorder

Sponsor

William Stoops

Enrollment

300 participants

Start Date

Jan 14, 2026

Study Type

INTERVENTIONAL

Conditions

Methamphetamine Use Disorder

Summary

Reduced drug use is a clinically meaningful target for treatment development, but few studies have evaluated the positive impacts produced by this behavioral change, preventing adoption of this endpoint in clinical trials. The proposed research will fill that critical knowledge gap by demonstrating the biopsychosocial benefits of reduced methamphetamine use. These data will be used to change current accepted methamphetamine treatment endpoints and accelerate identification of therapies for methamphetamine use disorder.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

be age 18 years or older;
self-report methamphetamine use in the week prior to screening;
provide a methamphetamine-positive urine sample at screening;
meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD);
be seeking treatment for their methamphetamine use
be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up
Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate.

Exclusion Criteria2

current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians
poor venous access precluding blood draws

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.